Navigation Links
New route to identify drugs that can fight bacterial infections
Date:7/28/2014

About 100 drugs already approved by the U.S. Food and Drug Administration (FDA) for other purposes can also prevent the growth of certain bacterial pathogens inside human cells, including those that cause Legionnaires' disease, brucellosis, and Mediterranean spotted fever. The findings, published in mBio, the online open-access journal of the American Society for Microbiology, demonstrate a new way of identifying non-antibiotic drugs that could one day help curb bacterial infections.

A handful of drugs on the list inhibit the growth of at least three of the four bacterial organisms tested. Those drugs include familiar compounds like loperamide, an antidiarrheal medication sold under the brand name Imodium and clemastine, an allergy medicine sold as Tavist, as well as drugs used to treat high blood pressure and angina.

Howard Shuman, professor of microbiology at the University of Chicago and a senior author on the study cautions that this study only looked at infection in the laboratory dish and therefore whether the drugs would effectively treat infections in humans is not known. The work, he says, is a good first step showing this method can identify FDA-approved drugs that might potentially act alongside traditional antibiotics.

"Antibiotic therapy is becoming more difficult to achieve, so looking for alternatives is always a good thing to do," Shuman says.

Shuman and his colleagues thought that certain types of bacteriathose that infect human cells and then replicate inside those cellsmight be vulnerable to other drug approaches.

"Intracellular bacteria resemble viruses in that they need host cell functions to complete their life cycle," says Shuman. So the researchers screened drugs to look for compounds that interfered with those cellular processes. They chose a panel of 640 FDA-approved drugs that have known safety and side effect profiles.

The researchers measured each drug's ability to disrupt the intracellular growth of four bacterial strains: Coxiella burnetii (which causes Q fever), Legionella pneumophila (Legionnaires' disease), Brucella abortus (brucellosis), and Rickettsia conorii (Mediterranean spotted fever). Although none of these organisms have become problem infections in the U.S. due to antibiotic resistance, brucellosis and Q fever can both cause chronic and ultimately fatal disease in about 5% of those infected.

The team screened each drug for its ability to reduce intracellular bacterial growth by 80% or more inside human THP-1 macrophage-like immune cells. They eliminated drugs from the list that simply killed off the human host cells or that were known antibiotic or antiviral drugs and identified 101 drugs that presumably disrupt key cellular functions in the host cells.

Shuman's lab group did the experiments on C. brunetii and L. pneumophila, while Sean Crosson's group at University of Chicago carried out the B. abortus work, and Juan Martinez's group, now at Louisiana State University in Baton Rouge, performed the R. conorii studies. The work, which was done at the Howard T. Ricketts Laboratory, a biocontainment laboratory operated by the University of Chicago in Lemont, Illinois, shows that known drugs that interfere with host cell properties can stall intracellular bacterial infections.

"There are emerging infections of all sortsbacteria, viruses, parasites. Working up a new therapy for such things take time," says Shuman. "If we have drugs X, Y, or Z to interfere with host cell functions to slow or impede an infection, then we can have something already on hand to attack it."


'/>"/>

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology
Source:Eurekalert

Related biology news :

1. How bumblebees find efficient routes without a GPS
2. A better route to xylan
3. Novel combination therapy shuts down escape route, killing glioblastoma tumor cells
4. Transmission routes of spreading protein particles
5. A fly mutation suggests a new route for tackling ALS
6. Antibiotics: Change route of delivery to mitigate resistance
7. A route for steeper, cheaper, and deeper roots
8. UT Arlington nanoparticles could provide easier route for cell therapy
9. Study provides insights into birds migration routes
10. Beyond the microscope: Identifying specific cancers using molecular analysis
11. Researchers identify new regulator in allergic diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)...  Veratad Technologies, LLC ( www.veratad.com ), an innovative ... verification solutions, announced today they will participate as a ... thru May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions ... evolving digital world, defining identity is critical to nearly ...
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
Breaking Biology News(10 mins):
(Date:8/11/2017)... ... 11, 2017 , ... “There is an increasing consumer call ... synthetic ingredients,” said Matt Hundt, President of Third Wave Bioactives. “Combining the strong ... know-how of Biorigin will allow us to bring truly novel fermented ingredient technologies ...
(Date:8/10/2017)... ... August 09, 2017 , ... ... applications in the clinic is here. The team at Capricor Therapeutics, Inc. utilized ... medium for clinical studies. , Dr. Travis Antes, head of analytical development ...
(Date:8/10/2017)... USA (PRWEB) , ... August 09, 2017 , ... ... partnered with four international biomedical optics laboratories — the Wellman Center for Photomedicine, ... Medical Laser Center Lübeck and the Beckman Laser Institute at University of California, ...
(Date:8/10/2017)... ... August 10, 2017 , ... CNA Finance Chief Research Analyst, ... on Next Group Holdings, Inc. and see's significant opportunity in the company's plans ... cannot engage in traditional banking services. According to industry estimates, approximately 103 million ...
Breaking Biology Technology: